Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023271 | 0.88 | PSEN1 (0.42) | MMP8MAPK1PSEN1PSEN2APH1B | |
| SCHEMBL1562512 | 0.82 | KMT2A (0.46) | METAP2GAAMAPK1KMT2APSEN1 | |
| SCHEMBL5023233 | 0.80 | MMP8 (0.60) | MMP8 | |
| SCHEMBL5016372 | 0.80 | METAP2 (0.37) | METAP2MMP8 | |
| SCHEMBL5026355 | 0.80 | METAP2 (0.41) | METAP2MAPK1RIPK1PSEN1PSEN2 | |
| SCHEMBL8310339 | 0.80 | ERCC1 (0.56) | METAP2GAAPSEN1PSEN2APH1B | |
| SCHEMBL5017857 | 0.79 | MAPK1 (0.43) | METAP2GAAMAPK1KMT2APSEN1 | |
| SCHEMBL5022524 | 0.78 | ROCK2 (0.40) | PDE10AMETAP2MAPK1RIPK1PSEN1 | |
| SCHEMBL5025121 | 0.78 | MAPK1 (0.40) | METAP2MAPK1KMT2ARIPK1PSEN1 | |
| SCHEMBL1561917 | 0.77 | METAP2 (0.38) | METAP2MMP8PSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592684-B1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7375099-B2 | secretase inhibitors; therapy for Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1592684-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | PDE10A 1416/4885METAP2 309/4885GAA 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.